Pfizer Cools To Tax Inversion After Nixed Allergan Deal
Pfizer Inc. said Tuesday it isn't inclined to seek another inversion transaction after it scrapped a proposed $160 billion merger with Irish drugmaker Allergan in April in light of the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article